// App-Quantinova.ai

2890 : Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials

Researchers

Presenter

  • Dominique Baeten

Principal Investigators

  • Ricardo Blanco

  • Piet Geusens

  • Joachim Sieper

  • Tseng Jui-Cheng

  • Ruvie Martin

  • Brian Porter

  • Hanno Richards

Medical Centers

  • Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

  • Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

  • Maastricht University, Maastricht, Netherlands

  • University Clinic Benjamin Franklin, Berlin, Germany

  • Hematology, Hospital Universitario Marques de Valdecilla, Santander, Spain

Locations

  • Germany

  • Taiwan

  • Spain

  • Netherlands

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

Biomarkers

  • High sensitivity C-reactive protein

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved